BioWorld Science

Oct. 1, 2012

View Archived Issues

GABAergic compound shows early promise in improving fragile X symptoms

Read More

Phase II trial begins for molecular imaging drug for prostate cancer

Read More

Amakem begins phase IIa AMA-0076 trial

Read More

University of Chicago designs novel anti-staphylococcal agents

Read More

Research at the University of Pennsylvania yields new cancer biotherapeutics

Read More

Novel AMPK activators disclosed in GSK patent

Read More

Seebri Breezhaler approved for COPD maintenance treatment in Japan

Read More

New York University presents new PGRN variants for inflammation

Read More

Pfizer obtains approval for Tygacil in Japan

Read More

Further clinical data reported on cancer vaccine MGN-1601 at ESMO

Read More

Neuralstem cleared to study NSI-566 in China

Read More

Novel BACE1 inhibitors created at Janssen Pharmaceutica

Read More

Phase I data on veliparib in patients with brain metastases reported

Read More

Roche presents new antidiabetic compounds

Read More

Dainippon Sumitomo Pharma obtains approval for Aimix combination tablets

Read More

Ariad completes rolling NDA submission for ponatinib

Read More

Novartis obtains Japanese approval for tobramycin

Read More

FDA expands approval of Venofer to pediatric patients

Read More

Phase III trial of OncoGenex' lead candidate commences in advanced NSCLC

Read More

Stem cell gene therapy shows promise in mucopolysaccharidosis IIIA model

Read More

Vital Therapies closes first stage of financing to fund phase III program for Elad

Read More

Osiris Therapeutics regains rights to Prochymal and Chondrogen

Read More

StemCells gives update on phase I/II chronic spinal cord injury study

Read More

Teva acquires Huntexil development program rights from NeuroSearch

Read More

Zosyn receives new indication approvals in Japan

Read More

Lotriga approved in Japan for the treatment of hyperlipidemia

Read More